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AF are similar in patients with and without VHD.
Perspective: Entrapment of a ring catheter within a prosthetic
valve can result in rapid hemodynamic decompensation.
Although entrapment occurred in only one patient in this
study, manual traction may not always be effective in freeing
the catheter. Therefore, it would seem prudent to avoid
introducing a ring catheter into the left atrium in patients
with a prosthetic mitral valve undergoing RFCA of AF.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Endovascular Stent-Grafts for the Treatment of
Abdominal Aortic Aneurysms: NICE Technology
Appraisal Guidance
Hay N, McCracken F, Richardson J, George E, Barnett D.
Heart 2009;95:1798–800.
Perspective: The top 10 points to remember about NICE
guidance on the use of stent-grafts to treat abdominal aortic
aneurysms (AAAs) are:
1: Endovascular aneurysm repair (EVAR) is recommended
as a treatment option in patients with infrarenal AAAs for
whom repair is considered appropriate.
2: Decisions as to whether to pursue EVAR or open AAA
repair should be made jointly by the patient and clinician.
3: Aneurysm size and morphology, patient age, life
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Arrhythmias
Pulmonary Vein Isolation Combined With Substrate
Modification for Persistent Atrial Fibrillation
Treatment in Patients With Valvular Heart Diseases
Wang X, Liu X, Shi H, et al.
Heart 2009;95:1773–1783.
Study Question: Is radiofrequency catheter ablation (RFCA) of
persistent atrial fibrillation (AF) safe and effective in patients
with valvular heart disease (VHD)?
Methods: Circumferential pulmonary vein isolation and abla-
tion of complex atrial electrograms were performed in 111
patients with persistent AF. Fifty-one patients had VHD
(44 patients had a prosthetic mitral valve) and 60 patients
did not have VHD. RFCA was performed with an irrigated-
tip catheter and a ring catheter was used to map the
pulmonary veins. Antiarrhythmic drug therapy was with-
drawn at 3 months of follow-up and a 24-hour Holter
monitor was performed at 2-month intervals. All patients
were followed for 12 months.
Results: Freedom from AF/atrial tachycardia did not differ sig-
nificantly between the patients with and without VHD (51%
and 55%, respectively). After redo procedures, freedom from
AF/atrial tachycardia also was similar in the patients with and
without VHD (67% and 72%, respectively). Catheter entrap-
ment in a prosthetic mitral valve occurred in one patient and
was successfully managed by manual traction.
Conclusions: The efficacy and safety of RFCA of persistent
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load of the LV, with LV dilation, hypertrophy, neuro-
humeral activation, and heart failure. Elevation of left atrial
pressure leads to left atrial enlargement, atrial fibrillation,
pulmonary venous congestion, and pulmonary hypertension.
4: There are no randomized trials comparing medical ther-
apy with surgery for MR caused by mitral valve prolapse.
However, some  studies suggest that survival is superior with
early surgical intervention. 
5: Mitral valve surgery can take the form of mitral valve
replacement or repair. There are no randomized trials com-
paring mitral valve repair and replacement for MR caused by
mitral valve prolapse. However, most observational studies
suggest that outcomes are superior with mitral valve repair. 
6: Surgical intervention generally is recommended for
chronic severe MR and the presence of any symptoms, LV
systolic dysfunction, significant LV enlargement, pulmonary
arterial hypertension, or new atrial fibrillation. When sur-
gery is indicated, current ACC/AHA and European Society
of Cardiology (ESC) guidelines recommend preferential use
of repair over replacement. If valve replacement is per-
formed, subvalvular chordal attachments should be
preserved.
7: There is debate regarding the use of ‘prophylactic’ mitral
valve repair, used to treat chronic severe MR in an asympto-
matic patient with none of the usual indications for surgery.
ACC/AHA guidelines recommend prophylactic mitral valve
repair if the likelihood of successful repair is >90%. 
8: Mitral valve repair is a specialized technique that should
be carried out by an experienced repair surgeon. Individual
and institutional experience is crucial; and high volumes are
associated with greater likelihood of valve repair rather than
replacement, and lower procedural mortality.
9: Surgical valve repair can include resection of redundant or
flail posterior segment(s); ‘sliding plasty’ to decrease poste-
rior leaflet height; and chordal transposition, use of artificial
chordae, and edge-to-edge repair for anterior leaflet pathol-
ogy.
10: Adverse outcomes from surgery include death, required
prolonged ventilatory support, renal insufficiency, stroke,
thromboembolism, and late recurrence of MR.
Summary written by: David S. Bach, MD
General Cardiology
Effectiveness of Public Report Cards for Improving
the Quality of Cardiac Care. The EFFECT Study: A
Randomized Trial
508 Eagle, Cannon
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expectancy and fitness, and long- and short-term benefits
and risks of the procedures should figure into the decision
about which route of AAA repair is appropriate.
4: EVAR should only be performed in centers of excellence
by clinical teams experienced in management of patients
with AAAs. 
5: EVAR was not recommended for ruptured AAAs, except
in the context of research. 
6: EVAR has lower medium-term reduced rates of operative
and aneurysm mortality. 
7: EVAR, however, is not associated with a reduction in all-
cause mortality long-term. EVAR is associated with
increased complications and reinterventions compared with
open repair. 
8: As most reports comparing open repair and EVAR use
older devices, the benefits of EVAR were likely greater than
that seen in randomized control trials. 
9: There was little or no difference in the initial procedure
costs between EVAR and open repair. 
10: In determining fitness for surgery, decisions over recom-
mending EVAR versus open repair should be made on an
individual basis, jointly between the patient and his/her cli-
nician.  
Summary written by: Gilbert Upchurch, Jr., MD
Mitral-Valve Repair for Mitral-Valve Prolapse
Verma S, Mesana TG.
N Engl J Med 2009;361:2261–2269.
Perspective: This summary describes a patient presenting
with myxomatous degeneration of the mitral valve and
severe mitral regurgitation (MR), and discusses the clinical
problem, benefits, and risks of mitral valve repair. Ten points
to remember are:
1: Mitral valve prolapse is the most common cause of MR in
developed countries, with a prevalence of ~2.5%. In some
patients, MR does not progress to severe, and life expectancy
is normal; in other patients (~5-10%), MR progresses to
severe, with adverse outcomes.
2: The mitral valve apparatus is comprised of mitral leaflets,
annulus, chordae tendinae, papillary muscles, and left ventric-
ular (LV) myocardium. The posterior mitral valve has three
scallops. MR can be caused by malcoaptation of myxomatous,
prolapsing leaflets, potentially exacerbated by mitral annular
dilation.
3: When present, chronic severe MR leads to volume over-
Results: There were no significant differences between
groups in change of global LV systolic function by echocar-
diography or magnetic resonance imaging (MRI) during
follow-up. On exercise testing, the mBMC-treated patients
had larger improvement in exercise time from 2-3 weeks to
3 years (1.5 minutes vs. 0.6 minutes, p = 0.05), but the
change in peak oxygen consumption did not differ (3.0
ml/kg/min vs. 3.1 ml/kg/min, p = 0.75).
Conclusions: Intracoronary mBMC treatment in AMI is safe
in the long-term. A small improvement in exercise time in
the mBMC group was found, but no other effects of treat-
ment could be identified 3 years after cell therapy.
Perspective: Previous studies of cell-based therapy for regenera-
tion of infarcted myocardium had mixed results, with some
trials reporting modest benefits. There does not appear to be a
major safety issue with intracoronary mBMC in this study;
however, the therapy appears largely ineffective. It may be
time to hold off on additional similar human clinical trials
until more effective forms of cell-based therapies demonstrate
consistent, reproducible myocardial replacement in preclinical
studies.  
Summary written by: Daniel T. Eitzman, MD 
Risk of Bleeding in Patients With Acute
Myocardial Infarction Treated With Different
Combinations of Aspirin, Clopidogrel, and Vitamin
K Antagonists in Denmark: A Retrospective
Analysis of Nationwide Registry Data
Sørensen R, Hansen ML, Abildstrom SZ, et al.
Lancet 2009;374:1967–1974.
Study Question: What is the long-term risk of bleeding among
patients with myocardial infarction (MI) who are treated
with aspirin, clopidogrel, or Coumadin, or any combination?
Methods: The authors used nationwide registries from
Denmark to identify patients ages ≥30 years who had been
admitted to the hospital with first-time MI between 2000
and 2005. Prescription claims starting at hospital discharge
were used to determine the regimen prescribed according to
the following groups: monotherapy with aspirin, clopido-
grel, or vitamin K antagonist; dual therapy with aspirin plus
clopidogrel, aspirin plus vitamin K antagonist, or clopidogrel
plus vitamin K antagonist; or triple therapy including all
three drugs. Risk of hospital admission for bleeding, recur-
rent MI, and death were assessed by Cox proportional
hazards models with the drug exposure groups as time-vary-
ing covariates.
Results: During a mean follow-up of 476 days, 1,852 (4.5%)
of 40,812 patients required hospitalization for a nonfatal
Tu JV, Donovan LR, Lee DS, et al.
JAMA 2009;302:2330–2337.
Study Question: Does public reporting of cardiac quality indi-
cators improve health care processes and patient outcomes?
Methods: The authors randomized 84 hospital corporations to
early (January 2004) or delayed (September 2005) feedback of
a public report card on their baseline performance (between
April 1999 and March 2001) on a set of 12 process-of-care
indicators for acute myocardial infarction (AMI) and 6 for
congestive heart failure (CHF). Follow-up performance data
(between April 2004 and March 2005) were collected.
Results: There was no difference in the composite AMI
process-of-care indicator (absolute change, 1.5%) or the
composite CHF process-of-care indicator (absolute change,
0.6%) between early versus late public report cards.
Conclusions: Public release of hospital-specific quality indica-
tors did not significantly improve composite process-of-care
indicators for AMI or CHF.
Perspective: This was a difficult randomized study to perform
and the null results may have been partly due to improved
performance of the control group (secondary to the
Hawthorne effect). Public reporting can also have unintended
consequences and carries significant cost. Although more open
availability of outcome data is generally good, it has been hard
to demonstrate whether the added cost of public reporting
delivers any value to patients or physicians.  
Summary written by: Hitinder S. Gurm, MBBS 
Long-Term Results After Intracoronary Injection of
Autologous Mononuclear Bone Marrow Cells in
Acute Myocardial Infarction: The ASTAMI
Randomised, Controlled Study
Beitnes JO, Hopp E, Lunde K, et al.
Heart 2009;95:1983–1989.
Study Question: What are the long-term clinical effects of
intracoronary injection of autologous mononuclear bone
marrow cell (mBMC) injection given in the setting of acute
myocardial infarction (AMI)?
Methods: One hundred patients from the randomized, con-
trolled ASTAMI study who underwent percutaneous coronary
intervention in the setting of anterior wall ST-elevation
myocardial infarction were re-assessed 3 years after inclusion.
Outcome measures were change in left ventricular (LV) ejec-
tion fraction (primary), change in exercise capacity (peak VO2)
and quality of life (secondary), infarct size (additional aim),
and safety.
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bleeding event. The annual incidence of bleeding was 2.6%
for the aspirin group, 4.6% for clopidogrel, 4.3% for vitamin
K antagonist, 3.7% for aspirin plus clopidogrel, 5.1% for
aspirin plus vitamin K antagonist, 12.3% for clopidogrel plus
vitamin K antagonist, and 12.0% for triple therapy.
Adjusted hazard ratios for bleeding were 1.33 for clopido-
grel, 1.23 for vitamin K antagonist, 1.47 for aspirin plus
clopidogrel, 1.84 for aspirin plus vitamin K antagonist, 3.52
for clopidogrel plus vitamin K antagonist, and 4.05 for triple
therapy. Patients with nonfatal bleeding were at a higher
risk of recurrent MI or death (37.9% vs. 18.4%) compared
with patients without any bleeding events. Mean time from
antithrombotic treatment to occurrence of a bleeding event
varied from 169 days for clopidogrel monotherapy to 275
days for monotherapy with a vitamin K antagonist. Most
nonfatal bleeding events were gastrointestinal.
Conclusions: Risk of hospital admission for bleeding increased
with the number of antithrombotic drugs used in patients
with MI.
Perspective: This study adds to evidence guiding physicians
contemplating use of Coumadin in patients with a recent
MI. Both triple and dual therapy with a vitamin K antago-
nist and clopidogrel was associated with extremely high risk
of bleeding. Triple therapy or combination of Coumadin
and clopidogrel should only be used after careful assessment
of the risk–benefit ratio of the individual patient.  
Summary written by: Hitinder S. Gurm, MBBS
Heart Failure/Transplant
The Yield of Risk Stratification for Sudden Cardiac
Death in Hypertrophic Cardiomyopathy Myosin-
Binding Protein C Gene Mutation Carriers: Focus
on Predictive Screening
Christiaans I, Birnie E, van Langen IM, et al.
Eur Heart J 2009;Dec. 16:[Epub ahead of print].
Study Question: What is the value of risk stratification with
genetic screening and clinical evaluations in patients with
MYBPC3 gene mutations?
Methods: Two hundred and thirty-five mutation carriers were
evaluated for the presence of hypertrophic cardiomyopathy
(HCM) and risk factors. A clinical diagnosis of HCM was
made in 53 carriers (22.6%).
Results: Disease penetrance was variable for all MYBPC3
gene mutations, and women were affected less often than
men (15% and 32%, respectively; p = 0.003). One risk factor
was present in 87 carriers and 9 had two or more risk factors.
Twenty-five carriers (11%) with one or more risk factors and
manifest HCM could be at risk for sudden cardiac death
(SCD).
Conclusions: At first evaluation, one-quarter of asymptomatic
carriers were diagnosed with HCM. Risk factors for SCD
were frequently present, and 11% of carriers could be at risk
for SCD. Predictive genetic testing in HCM families and
frequent cardiac evaluation for presence of HCM and risk
factors for SCD are justified until advanced age.
Perspective: Close clinical follow-up is indicated in relatives
of patients with HCM. Knowledge of the mutation status
may aid in follow-up if a likely causative mutation is identi-
fied. Most mutation carriers in the current study had the
same Dutch founder mutation. However, because of the
uncertainty of mutation causality in a diverse population and
incomplete penetrance of mutation carriers, the added value
of genetic testing remains unclear.  
Summary written by: Daniel T. Eitzman, MD
Use of Genetics in the Clinical Evaluation of
Cardiomyopathy
Judge DP.
JAMA 2009;302:2471–2476. 
Perspective: The following are 10 points to remember about
use of genetics in the clinical evaluation of cardiomyopathy:
1: Dilated cardiomyopathy (DCM) occurs in approximately
1 in 2,500 persons in the United States, and at least 20-
35% of these patients have an affected family member.
Every patient presenting with DCM should have a family
history taken, including information about CM, sudden
cardiac death, and syndromic features over at least three
generations.
2: Since early treatment with angiotensin-converting enzyme
(ACE) inhibitors has been shown to be beneficial in patients
with left ventricular (LV) dysfunction, recognition of
patients predisposed to DCM is clinically important.
3: Marked genetic heterogeneity complicates genetic testing
for CM. Mutations in more than 35 genes have been associ-
ated with DCM, and genetic testing is clinically available for
about half of these.
4: Mutations in the lamin A/C gene are found in 5-20% of
patients with DCM, and may result in a worse prognosis.
Ten percent of DCM patients have a mutation in a sarcom-
ere gene.  
5: Hypertrophic CM (HCM) occurs in about 1 in 500 persons
in the United States, and is the most common cause of sudden
measures were in-hospital bleeding and death.
Results: A contraindicated medication was used in 5,084
patients (22.3%). Of these, 2,375 (46.7%) received enoxa-
parin, 3,261 (64.1%) received eptifibatide, and 552 (10.9%)
received both. Receipt of a contraindicated medication was
associated with higher rates of in-hospital bleeding (5.6%
vs. 2.9%) and death (6.5% vs. 3.9%). After multivariable
adjustment, patients receiving contraindicated antithrom-
botics had significantly higher risks of in-hospital bleeding
and death. In 10,158 patients matched by propensity scores,
receipt of contraindicated antithrombotics remained signifi-
cantly associated with in-hospital bleeding, but not
in-hospital death. Among patients undergoing PCI with
acute coronary syndrome, the use of enoxaparin versus
unfractionated heparin, or eptifibatide versus abciximab was
associated with an increased risk of in-hospital major 
bleeding.
Conclusions: Use of enoxaparin and eptifibatide in patients on
dialysis was associated with a greater risk of bleeding.
Perspective: The fact that use of enoxaparin and eptifibatide
increases risk of bleeding in patients on dialysis is not a sur-
prise. I was, however, surprised by how commonly these
drugs are used in this population. Alternatives (unfraction-
ated heparin, bivalirudin, abciximab) that are safer in
patients on dialysis should be used to reduce the bleeding
risk in this population.  
Summary written by: Hitinder S. Gurm, MBBS 
Noninvasive Cardiology
Projected Cancer Risks From Computed
Tomographic Scans Performed in the United
States in 2007
de Gonzalez AB, Mahesh M, Kim K, et al.
Arch Intern Med 2009;169:2071–2077.
Study Question: What is the future cancer risk from current
computed tomographic (CT) scan use in the United States?
Methods: The authors estimated the frequency of different
types of CT scans performed using Medicare claims data
and the IMV Medical Information Division survey of CT
scan use in 2,451 US facilities in 2007. The age and sex dis-
tribution for each CT scan type was estimated using a large
national commercial insurance database. These estimates
were projected to the age-sex distribution of the US popula-
tion. Patients dying within 5 years of CT scan were
excluded.
death in young athletes. Most mutations identified are found
in sarcomere genes. Sarcomere mutations can thus cause either
HCM or DCM.
6: Fabry disease is an X-linked lysosomal storage disease
due to deficiency of α-galactosidase A that may lead to LV
hypertrophy, which is difficult to distinguish from HCM
due to other mutations. The Food and Drug
Administration has approved recombinant enzyme treat-
ment for this disease.
7: Familial amyloidosis may present with similar features to
other forms of HCM, but with echocardiograms showing LV
hypertrophy and electrocardiograms showing low voltage.
Familial cardiac amyloid is often due to mutations in the
transthyretin gene, and may be associated with neuropathy
and chronic diarrhea.
8: The development of genomic DNA sequencing chips will
reduce the cost and increase the feasibility of genetic testing to
become more widely applied in clinical practice; however,
translating the information into clinical practice will be a
major hurdle.
9: Genetic testing may provide the diagnostic gold standard
for screening of relatives, thus allowing for more vigilant fol-
low-up of those with positive testing. However, decisions
not to undergo screening are based on issues such as: 
a) concern about establishing a pre-existing condition, 
b) potential negative impact on future insurance premiums
and employment, and c) uncertainty regarding mutation
pathogenicity.
10: Genetic counseling should be provided prior to genetic
testing.
Summary written by: Daniel T. Eitzman, MD 
Interventional Cardiology
Contraindicated Medication Use in Dialysis
Patients Undergoing Percutaneous Coronary
Intervention 
Tsai TT, Maddox TM, Roe MT, et al., on behalf of the National
Cardiovascular Data Registry.
JAMA 2009;302:2458–2464.
Study Question: What are the implications and prevalence of
use of enoxaparin and eptifibatide in patients on dialysis
who undergo percutaneous coronary intervention (PCI)?
Methods: The authors evaluated the outcome of 22,778 dialy-
sis patients who underwent PCI between January 1, 2004,
and August 31, 2008, at 829 hospitals. The main outcome
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Results: The authors estimated that CT scans performed in
2007 may result in 29,000 (95% UL 15000-45000) excessive
malignancies. The largest risk was from scans of the
abdomen and pelvis (n = 14,000) (95% UL, 6,900-25,000),
followed by chest (n = 4,100) (95% UL, 1,900-8,100), and
head (n = 4,000) (95% UL, 1,100-8,700), and chest CT
angiography (n = 2,700) (95% UL, 1,300-5,000). Lung can-
cer was the most common projected radiation-related cancer
(n = 6,200) (95% UL, 2,300-13,000) followed by colon can-
cer (n = 3,500) and leukemia (n = 2,800). Approximately a
third of the projected cancers were due to scans performed
between the ages of 35 to 54 years compared with 15% of
those <18 years. The projected malignancies were expected
to be more common in females (66%).
Conclusions: Current CT scan use is expected to contribute to
a large number of future malignancies.
Perspective: This study adds to the growing awareness of
radiation risks associated with medical procedures, which
has resulted in lower use of radiation-based imaging in the
pediatric population; however, more needs to be done to
lower radiation use in young and middle-aged adults.
Dedicated quality improvement initiatives have been suc-
cessful at reducing radiation dose with CT angiography, and
similar efforts are needed to minimize the risk with all types
of CT scans.  
Summary written by: Hitinder S. Gurm, MBBS
Prevention/Vascular
Physical Exercise Prevents Cellular Senescence in
Circulating Leukocytes and in the Vessel Wall
Werner C, Fürster T, Widmann T, et al.
Circulation 2009;120:2438–2447. 
Study Question: What are the effects of exercising on vascular
telomere biology and endothelial apoptosis in mice, and
what are the effects of long-term endurance training on
telomere biology in humans?
Methods: C57/Bl6 mice were randomized to voluntary run-
ning or no running wheel conditions for 3 weeks. Exercise
telomerase activity was evaluated in the thoracic aorta and in
circulating mononuclear cells and compared with sedentary
controls. Telomere biology in circulating leukocytes of
young and middle-aged track and field athletes was analyzed
and compared to untrained individuals.
Results: Exercise upregulated telomerase activity in the tho-
racic aorta and in circulating mononuclear cells compared
with sedentary controls. Mice preconditioned by running
exhibited a marked reduction in lipopolysaccharide-induced
aortic endothelial apoptosis. Transgenic mouse studies
showed endothelial stress resistance after physical activity.
Peripheral blood leukocytes isolated from endurance athletes
showed increased telomerase activity, expression of telom-
ere-stabilizing proteins, and downregulation of cell-cycle
inhibitors compared with untrained individuals. Long-term
endurance training was associated with reduced leukocyte
telomere erosion compared with untrained controls.
Conclusions: Physical activity regulates telomere-stabilizing
proteins in mice and in humans and thereby protects from
stress-induced vascular apoptosis.
Perspective: Regular exercise training and better fitness are
associated with many positive effects including blood pressure
control, insulin sensitivity, less abdominal fat, better lipid pro-
file, reduction in systemic inflammatory markers, and
improved stress response. This study provides evidence for one
of many potential molecular explanations for decreasing car-
diovascular and overall mortality in fit men and women.  
Summary written by: Melvyn Rubenfire, MD
Effects of Liraglutide in the Treatment of Obesity:
A Randomised, Double-Blind, Placebo-Controlled
Study
Astrup A, Rössner S, Van Gaal L, et al., on behalf of the NN8022-1807
Study Group.
Lancet 2009;374:1606–1616. 
Study Question: What is the effect of liraglutide, a glucagon-
like peptide-1, on bodyweight and tolerability in obese
individuals without type 2 diabetes?
Methods: A double-blind, placebo-controlled 20-week trial,
with open-label orlistat comparator was conducted in 19 sites
in Europe. A total of 564 individuals (18-65 years of age,
body mass index 30-40 kg/m2) were randomly assigned, with
a telephone or web-based system, to one of four liraglutide
doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg, n = 90-95) or to
placebo (n = 98) administered once a day subcutaneously, or
orlistat (120 mg, n = 95) three times a day orally. All individ-
uals had a 500 kcal per day energy-deficit diet and increased
their physical activity throughout the trial. An 84-week open-
label extension followed.
Results: Mean weight loss with liraglutide 1.2-3.0 mg was 4.8
kg, 5.5 kg, 6.3 kg, and 7.2 kg compared with 2.8 kg with
placebo and 4.1 kg with orlistat, and was 2.1-4.4 kg greater
than that with placebo. More individuals (76%) lost more than
5% weight with liraglutide 3.0 mg than with placebo (30%) or
orlistat (44%) (p < 0.0001 for each). Liraglutide reduced blood
pressure at all doses, and reduced the prevalence of prediabetes
(84-96% reduction) with 1.8-3.0 mg per day.
Conclusions: Liraglutide treatment over 20 weeks is well toler-
ated, induces weight loss, improves certain obesity-related
risk factors, and reduces prediabetes.
Perspective: The GLP-1 class of drugs, including FDA
approved exenatide (Byetta®, Amlyin Pharmaceuticals), is
associated with a dose-dependent weight loss, improved
glycemic control and β-cell function, and lowers systolic
blood pressure. GLP-1 suppresses appetite and energy
intake. Long-term studies will be necessary to determine the
cost-effectiveness of this relatively expensive strategy com-
pared to metformin and other weight loss options.  
Summary written by: Melvyn Rubenfire, MD 
10-Year Follow-up of Diabetes Incidence and
Weight Loss in the Diabetes Prevention Program
Outcomes Study
Diabetes Prevention Program Research Group.
Lancet 2009;374:1677–1686.
Study Question: What is the persistence of benefit seen from
metformin and intensive lifestyle intervention in preventing
diabetes in high-risk patients enrolled in the Diabetes
Prevention Program (DPP) randomized clinical trial?
Methods: All participants in the three original DPP patient
groups (lifestyle intervention, metformin, placebo) were
offered lifestyle intervention in this follow-up study, due to
the demonstrated efficacy. The metformin group subjects con-
tinued therapy. Primary endpoint was development of
diabetes, according to American Diabetes Association criteria.
Analysis was by intention to treat.
Results: Among 3,150 original enrollees, 2,166 (88%) enrolled
for a median additional follow-up of 5.7 years, for a median
total follow-up of 10.0 years. The original lifestyle group lost,
then partly regained weight, and the metformin group main-
tained modest weight loss. Incidence rates of diabetes during
the original study were 4.8 cases per 100 person-years in the
lifestyle intervention group, 7.8 in the metformin group, and
11.0 in the placebo group. Incidence rates  were similar, at 5.9
per 100 person-years for lifestyle, 4.9 for metformin, and 5.6
for placebo. Diabetes incidence in the 10 years since DPP
randomization was reduced by 34% in the lifestyle group and
18% in the metformin group compared with placebo.
Conclusions: During extended follow-up, incidence rates for
diabetes in the former metformin and placebo groups
decreased to equal those in the former lifestyle group,
although the cumulative incidence of diabetes remained
lowest in the lifestyle group. Prevention or delay of diabetes
with lifestyle intervention or metformin can persist for at
least 10 years.
Perspective: The DPP study was an emphatic demonstration
JACC, Vol 55, No. 5, 2010
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of the profound impact lifestyle intervention can have on
development of diabetes. Important take-home points from
this and the initial study are: Lifestyle intervention (and
metformin) is highly effective in achieving weight loss and
preventing the development of diabetes in an at-risk popula-
tion. Blood pressure and lipid profiles improved with the
weight loss. More important will be an evaluation of the
cost-effectiveness of this lifestyle intervention, and the
applicability in real-life clinics.  
Summary written by: James B. Froehlich, MD 
Major Bleeding, Mortality, and Efficacy of
Fondaparinux in Venous Thromboembolism
Prevention Trials
Eikelboom JW, Quinlan DJ, O’Donnell M.
Circulation 2009;120:2006–2011.
Study Question: What is the association between major bleed-
ing and mortality as well as efficacy of fondaparinux versus
low molecular weight heparin (LMWH) or placebo for the
prevention of venous thromboembolism (VTE)?
Methods: The authors analyzed data combined from all ran-
domized, controlled trials of fondaparinux 2.5 mg daily versus
LMWH or placebo for the prevention of VTE during hip
fracture surgery, hip replacement surgery, major knee surgery,
elective abdominal surgery, or high-risk acutely ill medical
patients, in eight separate studies. They used Cox propor-
tional hazards modeling to study the association between
major bleeding and death at 30 days.
Results: Subjects developing major bleeding were older, more
likely male, had lower body weight and lower creatinine
clearance, and were more likely to receive fondaparinux.
Mortality risk was higher among subjects with major bleed-
ing (8.6% vs. 1.7%). Mortality was lower among subjects
treated with fondaparinux in the presence of major bleeding
(6.8% vs. 11.4%) or without major bleeding (1.5% vs. 1.9%;
p value for heterogeneity = 0.47).
Conclusions: Major bleeding in hospitalized surgical and
medical patients participating in VTE prevention trials is a
strong predictor of mortality.
Perspective: It is not surprising that major bleeding was asso-
ciated with increased mortality; but importantly,
fondaparinux was associated with improved mortality
regardless of the presence of major bleeding. One can also
conclude that the benefit from thromboprophylaxis with
fondaparinux outweighs any increased risk of bleeding; thus,
concern for bleeding risk in the setting of VTE prophylaxis
is misguided, and underestimates the benefit.  
Summary written by: James B. Froehlich, MD 
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C-Reactive Protein Concentration and Risk of
Coronary Heart Disease, Stroke, and Mortality: An
Individual Participant Meta-Analysis
The Emerging Risk Factors Collaboration.
Lancet 2009;Dec 22:[Epub ahead of print].
Study Question: What is the association of C-reactive protein
(CRP) concentration and risk of vascular and nonvascular out-
comes, and is the relationship causal?
Methods: A collaborative study using meta-analysis was con-
ducted between investigators of 54 prospective studies of
cardiovascular risk factors who provided data regarding CRP
and outcomes. The cohort included 160,309 people without a
history of vascular disease (i.e., 1.31 million person-years at
risk, 27,769 fatal or nonfatal disease outcomes). Within-study
regression analyses were adjusted for within-person variation
in risk factor levels. The primary outcome was coronary heart
disease (CHD), with subsidiary analyses of stroke by subtype,
death from vascular disease, and aggregate of nonvascular
death.
Results: Loge CRP concentration was linearly associated with
several conventional risk factors and inflammatory markers,
and nearly log-linearly with the risk of ischemic vascular dis-
ease and nonvascular mortality. Significant increases in risk
ratios (RRs) were found for CHD per 1-standard deviation
higher loge CRP concentration (threefold higher) RR 1.63
when initially adjusted for age and sex only, and RR 1.37
when adjusted further for conventional risk factors; 1.44 and
1.27 for ischemic stroke; 1.71 and 1.55 for vascular mortality;
and 1.55 and 1.54 for nonvascular mortality. After adjustment
for fibrinogen, corresponding RRs were 1.23 for CHD; 1.32
for ischemic stroke; 1.34 for vascular mortality; and 1.34 for
nonvascular mortality.
Conclusions: CRP concentration has continuous associations
with risk of CHD, ischemic stroke, vascular mortality, and
death from several cancers and lung disease that are each of
broadly similar size. Associations with ischemic vascular dis-
ease depend considerably on conventional risk factors and
other markers of inflammation.
Perspective: There is debate about the clinical utility of CRP
for risk assessment in cardiovascular disease as well as whether
it is a causal relationship or simply a biomarker of risk. This
study adds to the abundant literature supporting CRP as a risk
marker for cardiovascular events and mortality. This study
showing attenuation of attributable risk when corrected for
fibrinogen, and recent studies showing no relationship
between genetic polymorphisms associated with higher CRP
and cardiovascular disease imply that CRP is a risk marker,
but not a risk factor for cardiovascular events.  
Summary written by: Melvyn Rubenfire, MD
Association of Circulating Cholesteryl Ester
Transfer Protein Activity With Incidence of
Cardiovascular Disease in the Community
Vasan RS, Pencina MJ, Robins SJ, et al.
Circulation 2009;120:2414–2420.
Study Question: What is the relationship between plasma
cholesteryl ester transfer protein (CETP) activity and the
incidence of cardiovascular disease (CVD)?
Methods: Plasma CETP activity was measured in 1978
Framingham Heart Study participants (mean age, 51 years;
54% women) who attended a routine examination from 1987
to 1990 and were free of CVD. On follow-up (mean, 15.1
years), 320 participants experienced a first CVD event (fatal
or nonfatal coronary heart disease, cerebrovascular disease,
peripheral vascular disease, or heart failure).
Results: In adjusted multivariable analyses, plasma CETP
activity was related inversely to the incidence of CVD
events (hazard ratio [HR] for activity, at or above the
median of 0.72; 95% confidence interval, 0.57-0.90; p =
0.004 [compared with below median]; HR per standard
deviation increment, 0.86; 95% confidence interval, 0.76-
0.97; p = 0.01). The inverse association of CETP activity
with CVD incidence remained robust in time-dependent
models updating standard risk factors every 4 years, and was
maintained in analyses of incident “hard” CVD events
(myocardial infarction, stroke, or heart failure).
Conclusions: Lower plasma CETP activity was associated with
greater CVD risk. These observations, if confirmed, challenge
the concept that CETP inhibition may lower CVD risk.
Perspective: Although HDL levels are inversely related to
the risk of CVD, pharmacologic strategies designed to raise
HDL based on CETP inhibition have not produced benefi-
cial vascular effects, and may even be harmful. Studies
addressing relationships between genetic CETP abnormali-
ties and circulating CETP concentrations with CVD have
been controversial. The current study adds important
prospective data to this controversial area and suggests
CETP inhibitors will not have beneficial effects on CVD
events, and may lead to harm.  
Summary written by: Daniel T. Eitzman, MD
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